The Microbiome and Menopause: The Estrobolome

Two things, and they are entangled. The microbiome changes: studies comparing pre- and postmenopausal women find lower diversity after menopause and a shift in composition that makes a postmenopausal woman's gut community look, on average, more like a man's — a change that tracks estrogen loss rather than age alone, since it appears in surgical menopause too. And the estrogen the estrobolome has to work with falls to a fraction of what it was, so its influence on the small remaining pool is proportionally greater.

The direction of cause is not settled. Estrogen shapes the gut community; the gut community shapes estrogen exposure; and both are affected by the diet, weight, sleep and activity changes that come with the transition. The human studies are cross-sectional — snapshots — and cannot say which came first. What they can say is that the postmenopausal microbiome is measurably different, and that the difference is associated in observational work with the metabolic changes of the transition: weight gain around the middle, insulin resistance, and the cardiovascular risk that rises after menopause.

Associated, not shown to cause. That distinction is the whole of the next section.

A gut biome test reports diversity, composition and — depending on the method — the functional potential of the community, including whether the genes for beta-glucuronidase are abundant. That is the estrobolome, in the sense that it is the presence of the machinery.

What it does not report is how much estrogen recycling is actually happening, because gene presence is not enzyme activity, and enzyme activity is not reabsorbed estrogen. The test tells you the community has the tools; it does not tell you how much they are being used, or what your circulating estrogen would be without them. The only way to know your estrogen exposure is to measure estrogen — on the baseline panel — and a woman deciding about hormone therapy needs that number and her symptoms, not a beta-glucuronidase abundance.

Nor can the test tell you what to do. There is no trial in which changing the estrobolome — with probiotics, fiber, calcium-D-glucarate or anything else — changed a woman's menopausal symptoms, her bone density or her cardiovascular outcomes. Fiber and a plant-rich diet raise diversity and are good for other reasons; the supplements sold specifically to "modulate the estrobolome" have no outcome evidence.

The estrobolome is a mechanism worth understanding, because it explains something real about why estrogen exposure varies and why the postmenopausal gut matters. It is not a target. A woman with menopausal symptoms is treated for menopausal symptoms — the women's HRT page covers the evidence — and her microbiome is not a reason to delay that or a substitute for it.

Where the test earns its place is the question on the main page: a woman with persistent digestive symptoms, or one who wants a baseline before changing her diet substantially, gets useful information from it. A woman who has been told her menopause can be managed through her microbiome has been told something the evidence does not support, and we would rather say so.